The Continuous Learning Curve: CPI’s Simon Hawdon on Process Conversion, Product Quality, and Platform Selection

September 13, 2022

In the inaugural episode of Evaluating Biopharma podcast, CPI’s Simon Hawdon speaks with Moderator John Bonham-Carter about the benefits of converting from batch to continuous processing and the critical decisions involved in making a high-quality product. Hawdon talks about whether there is an optimal time for process conversion, key equipment features that facilitate automation, and why improved sensors are imperative for process development. Finally, Hawdon shares his predictions on when he thinks real-time release sensors will debut and why necessity will always drive industry growth.

Simon Hawdon, Principal Scientist, CPI National Biologics Manufacturing Centre
Simon Hawdon has been working on continuous manufacturing since 2017 through collaborative R&D projects with industrial partners to develop proof of concept systems and advance technology readiness levels in this field. Hawdon has more than 30 years of experience in the biotechnology industry in the UK, including Lonza and Merck Millipore.

Sponsor:

Asahi Kasei Bioprocess dependably supplies innovative yet exceptionally reliable bioprocess equipment, consumables, and scientific support services to help manufacturers of regulated therapeutics safely and efficiently produce medicines that patients can trust.

Leveraging its core technology, brand, and services in bioprocess equipment, Asahi Kasei Bioprocess’ mission is to be the leader and expert in contributing to the safety and manufacturing efficiency of therapeutic proteins, oligonucleotides, and peptides.